Javitt JC - Search Results

1

Using a claims data-based sentinel system to improve compliance with clinical guidelines: results of a randomized prospective study.

Javitt JC, Steinberg G, Locke T, Couch JB, Jacques J, Juster I, Reisman L. Javitt JC, et al. Am J Manag Care. 2005 Feb;11(2):93-102. Am J Manag Care. 2005. PMID: 15726857 Free article. Clinical Trial.

2

Information technology and medical missteps: evidence from a randomized trial.

Javitt JC, Rebitzer JB, Reisman L. Javitt JC, et al. J Health Econ. 2008 May;27(3):585-602. doi: 10.1016/j.jhealeco.2007.10.008. Epub 2007 Dec 4. J Health Econ. 2008. PMID: 18199511

3

Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss.

Javitt JC, Zhou Z, Willke RJ. Javitt JC, et al. Ophthalmology. 2007 Feb;114(2):238-45. doi: 10.1016/j.ophtha.2006.07.054. Ophthalmology. 2007. PMID: 17270673

4

Using Medicare claims for outcomes research.

Mitchell JB, Bubolz T, Paul JE, Pashos CL, Escarce JJ, Muhlbaier LH, Wiesman JM, Young WW, Epstein RS, Javitt JC. Mitchell JB, et al. Among authors: javitt jc. Med Care. 1994 Jul;32(7 Suppl):JS38-51. Med Care. 1994. PMID: 8028412

5

Incidence of exudative age-related macular degeneration among elderly Americans.

Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Javitt JC, et al. Ophthalmology. 2003 Aug;110(8):1534-9. doi: 10.1016/S0161-6420(03)00495-0. Ophthalmology. 2003. PMID: 12917168

6

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP. Javitt JC, et al. Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17. Value Health. 2008. PMID: 18179676 Free article. Clinical Trial.

7

Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the medicare population.

Zlateva GP, Javitt JC, Shah SN, Zhou Z, Murphy JG. Zlateva GP, et al. Among authors: javitt jc. Retina. 2007 Nov-Dec;27(9):1292-9. doi: 10.1097/01.iae.0000300915.81866.b8. Retina. 2007. PMID: 18046240

8

Health economic analysis of micronutrient supplementation: the World Bank perspective.

Javitt JC. Javitt JC. Public Health Rev. 2000;28(1-4):159-62. Public Health Rev. 2000. PMID: 11411269 No abstract available.

9

Cost-effectiveness of detecting and treating diabetic retinopathy.

Javitt JC, Aiello LP. Javitt JC, et al. Ann Intern Med. 1996 Jan 1;124(1 Pt 2):164-9. doi: 10.7326/0003-4819-124-1_part_2-199601011-00017. Ann Intern Med. 1996. PMID: 8554212

10

Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization?

Fendrick AM, Javitt JC, Chiang YP. Fendrick AM, et al. Among authors: javitt jc. Int J Technol Assess Health Care. 1992 Fall;8(4):694-707. doi: 10.1017/s0266462300002385. Int J Technol Assess Health Care. 1992. PMID: 1464489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page